ConductScience.org, home

Paper235486

Red cell abnormalities associated with sulphasalazine maintenance therapy for ulcerative colitis.

Pounder RE and 3 others. Gut, 1975. Cited by 52 papers, by iCite.

Cite this record

ConductScience Library. Red cell abnormalities associated with sulphasalazine maintenance therapy for ulcerative colitis. Papers, record 235486. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/235486

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Red cell abnormalities associated with sulphasalazine maintenance therapy for ulcerative colitis.
PubMed
Journal
Gut
PubMed
Year
1975
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
52
iCite
Relative citation ratio, by iCite
2.29
iCite
Revised in PubMed
2019-05-01
PubMed

Authors4

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Pounder RER E
2Craven ERE R
3Henthorn JSJ S
4Bannatyne JMJ M

Source PubMed

Download CSV of authors

Topics12

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Colitis, UlcerativeMajor topic
Erythrocytes, AbnormalMajor topic
Hematologic DiseasesMajor topic
SulfasalazineMajor topic
Anemia, Hemolytic
Erythrocyte Count
Heinz Bodies
Hematocrit
Humans
Methemoglobinemia
Pyridines
Reticulocytes

Source PubMed

Download CSV of topics

References15

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
14145285Determination of sulphapyridine and its metabolites in biological materials after administration of salicylazosulphapyridine.Acta Pharm Suec1973https://conductscience.org/library/papers/4145285PubMed
24148104Letter: Hemolytic anemia as adverse reaction to salicylazosulfapyridine.N Engl J Med1973https://conductscience.org/library/papers/4148104PubMed
34146729Adverse reactions during salicylazosulfapyridine therapy and the relation with drug metabolism and acetylator phenotype.N Engl J Med1973https://conductscience.org/library/papers/4146729PubMed
44147555The metabolism of salicylazosulphapyridine in ulcerative colitis. I. The relationship between metabolites and the response to treatment in inpatients.Gut1973https://conductscience.org/library/papers/4147555PubMed
54150435A controlled therapeutic trial of long-term maintenance treatment of ulcerative colitis with sulphazalazine (Salazopyrin).Gut1973https://conductscience.org/library/papers/4150435PubMed
614050794THE OCCURRENCE OF HEINZ BODIES DURING AZULFIDINE TREATMENT OF ULCERATIVE COLITIS.Gastroenterologia1963https://conductscience.org/library/papers/14050794PubMed
714238045PREDNISONE AS MAINTENANCE TREATMENT FOR ULCERATIVE COLITIS IN REMISSION.Lancet1965https://conductscience.org/library/papers/14238045PubMed
814218553CONTROLLED TRIAL OF SULPHASALAZINE IN THE TREATMENT OF ULCERATIVE COLITIS.Gut1964https://conductscience.org/library/papers/14218553PubMed
914197149HEMOLYTIC ANEMIA SECONDARY TO SALICYLAZOSULFAPYRIDINE THERAPY.JAMA1964https://conductscience.org/library/papers/14197149PubMed
1013967788Drug-associated blood dyscrasias. Recent additions to the Registry.JAMA1963https://conductscience.org/library/papers/13967788PubMed
124136052Hyposplenism in ulcerative colitis.Lancet1974https://conductscience.org/library/papers/4136052PubMed
134137782Letter: Hyposplenism in ulcerative colitis.Lancet1974https://conductscience.org/library/papers/4137782PubMed
144402420Acetylator phenotype and adverse effects of sulphasalazine in healthy subjects.Gut1972https://conductscience.org/library/papers/4402420PubMed
154402886Absorption, metabolism, and excretion of salicylazosulfapyridine in man.Clin Pharmacol Ther1972https://conductscience.org/library/papers/4402886PubMed
164386139Ulcerative colitis and erythrocyte G6PD deficiency. Salicylazosulfapyridine-provoked hemolysis.JAMA1968https://conductscience.org/library/papers/4386139PubMed

Download CSV of references

Cited by13

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 52 citations.

PMIDTitleJournalYearIn PapersSource
31824960The Role of Iron Regulation in Immunometabolism and Immune-Related Disease.Front Mol Biosci2019https://conductscience.org/library/papers/31824960PubMed
7945999The role of active metabolites in drug toxicity.Drug Saf1994https://conductscience.org/library/papers/7945999PubMed
7851193Safety and efficacy of controlled-release mesalamine for maintenance of remission in ulcerative colitis. Pentasa UC Maintenance Study Group.Dig Dis Sci1995https://conductscience.org/library/papers/7851193PubMed
6136396Sulfasalazine. Adverse effects and desensitization.Dig Dis Sci1983https://conductscience.org/library/papers/6136396PubMed
6114899Role of sulphasalazine in the aetiology of folate deficiency in ulcerative colitis.Gut1981https://conductscience.org/library/papers/6114899PubMed
6105118Optimum dose of sulphasalazine for maintenance treatment in ulcerative colitis.Gut1980https://conductscience.org/library/papers/6105118PubMed
2877847Sulphasalazine: a review of 40 years' experience.Drugs1986https://conductscience.org/library/papers/2877847PubMed
2874103Sulphasalazine associated pancytopenia may be caused by acute folate deficiency.Gut1986https://conductscience.org/library/papers/2874103PubMed
2872667Megaloblastic anaemia due to sulphasalazine responding to drug withdrawal alone.Postgrad Med J1986https://conductscience.org/library/papers/2872667PubMed
2563951Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial.BMJ1989https://conductscience.org/library/papers/2563951PubMed
1685664Direct and metabolism-dependent toxicity of sulphasalazine and its principal metabolites towards human erythrocytes and leucocytes.Br J Clin Pharmacol1991https://conductscience.org/library/papers/1685664PubMed
456215Autoimmune hemolytic anemia in ulcerative colitis: report of three cases, review of the literature, and evaluation of modes of therapy.Dig Dis Sci1979https://conductscience.org/library/papers/456215PubMed
15752Clinical pharmacokinetics of sulphasalazine.Clin Pharmacokinet1976https://conductscience.org/library/papers/15752PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/235486

GET https://conductscience.org/api/papers/v1/235486/authors